Journal Information
Vol. 6. Issue 6.
Pages 292-295 (November - December 2010)
Download PDF
More article options
Vol. 6. Issue 6.
Pages 292-295 (November - December 2010)
Full text access
Primary Sjögren's syndrome: Expression of NF-κB in minor salivary glands
Síndrome de Sjögren primario: expresión del factor NF-κB en glándula salival menor
Liliana Villalona,
Corresponding author

Corresponding author.
, Marta Mamanib, Felix E. Romaninib, Antonio Catalan Pelletb, Alejandro Berraa
a Laboratorio de Investigaciones Oculares, Departamento de Patología, Facultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina
b Servicio de Reumatología, Hospital Bernardino Rivadavia, Buenos Aires, Argentina
This item has received
Article information
Download PDF

To evaluate nuclear NF-κB translocation in minor salivary glands (mSG) of human primary Sjogren Syndrome (pSS).


Lip biopsies’ mSG were done in 24 female patients with pSS from the Rheumatology Service of Rivadavia Hospital. Glands were stained with H&E and immunostained for NF-κB. Specimens were classified according to the Chisholm and Masson score.


The biopsies (H&E staining) showed lymphoplasmocitic infiltrates, forming periacini and periductal focuses which number depending on the stage of the disease. In stages III and IV there was acini destruction and, in some cases, fibrosis. In the biopsies with a diagnosis of sialadenitis we observed interstitially-dispersed lymphoplasmocitic elements and also polimorphonuclear neutrophils. The lip biopsies’ mSG of patients with clinical-serological diagnosis of pSS showed nuclear translocation of NF-κB in lymphocytes of focal infiltrates and in the acini epithelium adjacent to the infiltrates. In distal acini and ductal structures from the infitrates we did not observe nuclear translocation. However, in SSp patients with sialadenitis interstitial lymphocytes with nuclear translocation were observed but neither in the acini or the ducts. SSp patients with normal glands did not show nuclear translocation of NF-κB factor either in the acini or in the ducts.


These results allow us to infer the importance of lymphocyte-epithelium interaction on the activation of NF-κB in human pSS.

Primary Sjögren's syndrome
Expression of NF-κB in minor salivary glands

Evaluar la translocacion nuclear del factor NF-κB en las glandulas salivales menores de pacientes con sindrome de Sjogren primario (SSp).


Se realizaron biopsias de glandulas salivares menores en 24 pacientes mujeres con diagnostico de SSp del Servicio de Reumatologia del Hospital Rivadavia. Las glandulas fueron tenidas con H&E y la inmunohistoquimica para NF-κB, fueron clasificados de acuerdo con la puntuacion de Chisholm y Masson.


Las biopsias de pacientes con SSp (H&E) mostraron infiltrados linfoplasmocitarios, formando focos periacinares y periductales cuyo numero depende del estadio de la enfermedad. En las fases III y IV se observa la destruccion de los acinos y, en algunos casos, fibrosis. En las biopsias con diagnostico de sialoadenitis observamos elementos linfoplasmocitarios intersticiales dispersos y tambien neutrofilos polimorfonucleares. Las biopsias de labio de pacientes con diagnostico clinico serologico de SSp mostraron la translocacion nuclear de NF-κB en los linfocitos de infiltracion focal y en el epitelio de los acinos adyacentes a los infiltrados. En acinos y en las estructuras ductales alejadas de los infiltrados, no observamos translocacion nuclear. Sin embargo, en pacientes con sialoadenitis se observaron linfocitos intersticiales con translocacion nuclear pero no en acinos y ductos. Los pacientes con SSp con glandula normal no mostraron translocacion nuclear del factor NF-κB, ni en acinos ni en el conducto.


Estos resultados nos permiten inferir la importancia de la interaccion linfocitosepitelio y la activacion del factor NF-κB en pacientes con diagnostico de SSp.

Palabras clave:
Síndrome de Sjogren
Autoinmunidad NF-κB en glándulas salivales
Full text is only aviable in PDF
N. Talal.
Sjogren's syndrome.
Curr Opin Immunol, 2 (1989), pp. 622-624
R.I. Fox.
Sjogren's syndrome.
Curr Opin Rheumatol, 7 (1995), pp. 409-416
C. Vitali, S. Bombardieri, H.M. Moutsopoulos, J. Coll, R. Gerli, P.Y. Hatron, et al.
Assessment of the European classification criteria for Sjogren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjogren's Syndrome.
Ann Rheum Dis, 55 (1996), pp. 116-121
J.G. Brun, T.M. Madland, C.B. Gjesdal, L.T. Bertelsen.
Sjogren's syndrome in an outpatient clinic: classification of patients according to the preliminary European criteria and the proposed modified European criteria.
Rheumatology (Oxford), 41 (2002), pp. 301-304
K.J. Bloch, W.W. Buchanan, M.J. Wohl, J.J. Bunim.
Sjoegren's syndrome. A Clinical, pathological, and serological study of sixty-two cases.
Medicine (Baltimore), 44 (1965), pp. 187-231
T.E. Daniels.
Salivary histopathology in diagnosis of Sjogren's syndrome.
Scand J Rheumatol Suppl, 61 (1986), pp. 36-43
R.I. Fox.
Sjogren's syndrome.
A. Hansen, P.E. Lipsky, T. Dorner.
New concepts in the pathogenesis of Sjogren syndrome: many questions, fewer answers.
Curr Opin Rheumatol, 15 (2003), pp. 563-570
S. Bacman, A. Berra, L. Sterin-Borda, E. Borda.
Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjogren syndrome.
Invest Ophthalmol Vis Sci, 42 (2001), pp. 321-327
T. Watanabe, T. Tsuchida, N. Kanda, K. Mori, Y. Hayashi, K. Tamaki.
Anti-alpha-fodrin antibodies in Sjogren syndrome and lupus erythematosus.
Arch Dermatol, 135 (1999), pp. 535-539
F.H. Sarkar, Y. Li, Z. Wang, D. Kong.
NF-kappaB signaling pathway and its therapeutic implications in human diseases.
Int Rev Immunol, 27 (2008), pp. 293-319
K.D. Brown, E. Claudio, U. Siebenlist.
The roles of the classical and alternative nuclear factor-kappaB pathways: potential implications for autoimmunity and rheumatoid arthritis.
Arthritis Res Ther, 10 (2008), pp. 212
M.N. Manoussakis, I.D. Dimitriou, E.K. Kapsogeorgou.
Expression of B7 costimulatory molecules by salivary gland epithelial cells in patients with Sjogren's syndrome.
C. Vitali, S. Bombardieri, R. Jonsson, H.M. Moutsopoulos, E.L. Alexander, S.E. Carsons, et al.
Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.
Ann Rheum Dis, 61 (2002), pp. 554-558
D.M. Chisholm, D.K. Mason.
Labial salivary gland biopsy in Sjogren's disease.
J Clin Pathol, 21 (1968), pp. 656-660
M.S. Hayden, S. Ghosh.
Signaling to NF-kappaB.
Genes Dev, 18 (2004), pp. 2195-2224
P. Perez, Y.J. Kwon, C. Alliende, L. Leyton, S. Aguilera, C. Molina, et al.
Increased acinar damage of salivary glands of patients with Sjogren's syndrome is paralleled by simultaneous imbalance of matrix metalloproteinase 3/tissue inhibitor of metalloproteinases 1 and matrix metalloproteinase 9/tissue inhibitor of metalloproteinases 1 ratios.
Arthritis Rheum, 52 (2005), pp. 2751-2760
P.C. Lucas, L.M. McAllister-Lucas, G. Nunez.
NF-kappaB signaling in lymphocytes: a new cast of characters.
J Cell Sci, 117 (2004), pp. 31-39
M. Ek, K. Popovic, H.E. Harris, C.S. Naucler, M. Wahren-Herlenius.
Increased extracellular levels of the novel proinflammatory cytokine high mobility group box chromosomal protein 1 in minor salivary glands of patients with Sjogren's syndrome.
Arthritis Rheum, 54 (2006), pp. 2289-2294
R. Pullerits, I.M. Jonsson, M. Verdrengh, M. Bokarewa, U. Andersson, H. Erlandsson-Harris, et al.
High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis.
Arthritis Rheum, 48 (2003), pp. 1693-1700
M. Azuma, K. Motegi, K. Aota, Y. Hayashi, M. Sato.
Role of cytokines in the destruction of acinar structure in Sjogren's syndrome salivary glands.
Lab Invest, 77 (1997), pp. 269-280
J.L. Martindale, N.J. Holbrook.
Cellular response to oxidative stress: signaling for suicide and survival.
J Cell Physiol, 192 (2002), pp. 1-15
Copyright © 2010. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Reumatología Clínica (English Edition)
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?